Literature DB >> 25139535

HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.

Matthew James Ellis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25139535     DOI： 10.1093/jnci/dju212

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

Authors:  Ciara C O'Sullivan; Ian Bradbury; Christine Campbell; Marc Spielmann; Edith A Perez; Heikki Joensuu; Joseph P Costantino; Suzette Delaloge; Priya Rastogi; Dimitrios Zardavas; Karla V Ballman; Eileen Holmes; Evandro de Azambuja; Martine Piccart-Gebhart; Jo Anne Zujewski; Richard D Gelber
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

2.  Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy.

Authors:  Xinguang Wang; Yingjian He; Zhaoqing Fan; Tianfeng Wang; Yuntao Xie; Jinfeng Li; Tao Ouyang
Journal:  Breast Care (Basel)       Date:  2019-02-05       Impact factor: 2.860
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.